A European study offers more evidence that weekly injections of interferon beta reduce the risk that people with early symptoms of multiple sclerosis will progress to the full-blown disease within two years.The study, in this week’s issue of The Lancet, found that interferon beta reduced the loss of brain tissue in these early stage MS patients, compared to those who received a placebo.
